302 related articles for article (PubMed ID: 20460554)
1. Saxagliptin: a new dipeptidyl peptidase 4 inhibitor for type 2 diabetes.
Borja-Hart NL; Whalen KL
Ann Pharmacother; 2010 Jun; 44(6):1046-53. PubMed ID: 20460554
[TBL] [Abstract][Full Text] [Related]
2. Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Gallwitz B
IDrugs; 2008 Dec; 11(12):906-17. PubMed ID: 19051153
[TBL] [Abstract][Full Text] [Related]
3. Exploration of the DPP-4 inhibitors with a focus on saxagliptin.
Shubrook JH; Colucci RA; Schwartz FL
Expert Opin Pharmacother; 2009 Dec; 10(17):2927-34. PubMed ID: 19929711
[TBL] [Abstract][Full Text] [Related]
4. Saxagliptin and tuberculosis.
Prescrire Int; 2013 Jan; 22(134):17. PubMed ID: 23383408
[No Abstract] [Full Text] [Related]
5. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Deacon CF; Holst JJ
Adv Ther; 2009 May; 26(5):488-99. PubMed ID: 19444391
[TBL] [Abstract][Full Text] [Related]
6. Saxagliptin efficacy.
Valiquette G
Diabetes Obes Metab; 2010 Aug; 12(8):734; author reply 735. PubMed ID: 20590752
[No Abstract] [Full Text] [Related]
7. Saxagliptin for the treatment of type 2 diabetes mellitus: focus on recent studies.
Schwartz SL
Ann Med; 2012 Mar; 44(2):157-69. PubMed ID: 22132773
[TBL] [Abstract][Full Text] [Related]
8. Saxagliptin. No more effective than other gliptins, but a high potential for drug interactions.
Prescrire Int; 2011 Feb; 20(113):33-7. PubMed ID: 21488586
[TBL] [Abstract][Full Text] [Related]
9. No benefit of saxagliptin on cardiovascular outcomes in type 2 diabetes mellitus: potential explanations.
Jialal I; Dhindsa S
Metab Syndr Relat Disord; 2014 Apr; 12(3):157-8. PubMed ID: 24520851
[No Abstract] [Full Text] [Related]
10. Saxagliptin demonstrates no increased risk for cardiovascular death, heart attack or stroke in the SAVOR cardiovascular outcomes trial.
Hardy G
Cardiovasc J Afr; 2013 Aug; 24(7):290. PubMed ID: 24217308
[No Abstract] [Full Text] [Related]
11. [Dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin. Cardiovascular safety in type 2 diabetics].
MMW Fortschr Med; 2014 Jul; 156(13):74-5. PubMed ID: 25318234
[No Abstract] [Full Text] [Related]
12. Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus.
Neumiller JJ; Campbell RK
Am J Health Syst Pharm; 2010 Sep; 67(18):1515-25. PubMed ID: 20811029
[TBL] [Abstract][Full Text] [Related]
13. [DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].
Gallwitz B
Pharm Unserer Zeit; 2010 Mar; 39(2):114-8. PubMed ID: 20196038
[No Abstract] [Full Text] [Related]
14. Saxagliptin (Onglyza) for type 2 diabetes.
Med Lett Drugs Ther; 2009 Nov; 51(1324):85-6. PubMed ID: 19890244
[No Abstract] [Full Text] [Related]
15. Baseline differences in the SAVOR trial.
Luijendijk HJ; Hulshof TA
Diabetes Obes Metab; 2015 Dec; 17(12):1202. PubMed ID: 26094750
[No Abstract] [Full Text] [Related]
16. Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus.
Hirshberg B; Parker A; Edelberg H; Donovan M; Iqbal N
Diabetes Metab Res Rev; 2014 Oct; 30(7):556-69. PubMed ID: 24376173
[TBL] [Abstract][Full Text] [Related]
17. Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety.
Jain R
Adv Ther; 2015 Nov; 32(11):1065-84. PubMed ID: 26578430
[TBL] [Abstract][Full Text] [Related]
18. Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial.
Mosenzon O; Raz I; Scirica BM; Hirshberg B; Stahre CI; Steg PG; Davidson J; Ohman P; Price DL; Frederich B; Udell JA; Braunwald E; Bhatt DL
Diabetes Metab Res Rev; 2013 Jul; 29(5):417-26. PubMed ID: 23564755
[TBL] [Abstract][Full Text] [Related]
19. Saxagliptin, alone or in combination. No fewer complications; more cases of heart failure?
Prescrire Int; 2014 Sep; 23(152):207. PubMed ID: 25325118
[TBL] [Abstract][Full Text] [Related]
20. Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes.
Del Prato S
Int J Clin Pract Suppl; 2007 Aug; (154):38-48. PubMed ID: 17593276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
